NCT07014709Not yet recruiting
Impact of GLP-1 Receptor Agonists on Patients With IPMN
Impact of GLP-1 Receptor Agonists on Patients With Intraductal Papillary Mucinous Neoplasms: A Retrospective Multicentric Cohort Study
Source: ClinicalTrials.gov · Last updated 11 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study investigates the impact of GLP-1 receptor agonists (GLP-1 RAs) on patients with intraductal papillary mucinous neoplasms (IPMNs), a type of pancreatic cystic neoplasm that can progress to malignancy. With the increasing use of GLP-1 RAs for managing diabetes and obesity, concerns about their potential to influence pancreatic conditions, like IPMNs, have emerged. Although GLP-1 RAs are generally safe, their effects on pre-existing pancreatic conditions remain unclear. The study aims to evaluate whether GLP-1 RA use in IPMN patients is linked to changes in pancreatic cyst characteristics, the incidence of acute pancreatitis, variations in tumor markers, and the progression of IPMNs to high-grade dysplasia or malignancy. A retrospective analysis will be conducted using medical data from patients diagnosed with IPMNs and treated with GLP-1 RAs between 2010 and 2024 at three Swiss hospitals. Key outcomes will include radiological changes, the incidence of acute pancreatitis, and potential shifts in IPMN surveillance or need for surgical intervention
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 30 Apr 2025
- Start date
- 31 May 2025
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Hôpital Fribourgeois
- Diseases
- Pancreatic cancer
- NCT number
- NCT07014709
What you commit to
- Study type: Observational
- Planned participants: 30
- From 31 May 2025 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- no documented history of GLP-1 RAs use
Other
- radiological diagnosis of IPMN is unclear,
- patients did not provide signed informed consent, or have documented refusal for research.
Who the study is looking for
- \> 18 years old
- Radiological diagnosis of IPMN
- Treated with GLP-1 RAs.
- Patients must have provided prior informed consent for the use of their coded clinical data in research.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| HFR Hopital fribourgeois Coordinator of this site? Confirm its status | Villars-sur-Glâne | Switzerland | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.